These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 17489733

  • 1. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 2. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 3. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 4. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.
    J Clin Oncol; 2007 Jul 01; 25(19):2741-6. PubMed ID: 17602079
    [Abstract] [Full Text] [Related]

  • 5. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 01; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 6. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC, Hwang TS.
    Lung Cancer; 2004 Jun 01; 44(3):311-6. PubMed ID: 15140544
    [Abstract] [Full Text] [Related]

  • 7. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 01; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 8. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C, Ren S, Zhou S, Zhang L, Su C, Zhang Z, Deng Q, Zhang J.
    Jpn J Clin Oncol; 2010 Oct 01; 40(10):954-60. PubMed ID: 20462983
    [Abstract] [Full Text] [Related]

  • 9. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 10. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul 01; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 11. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 12. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
    Li F, Sun X, Sun N, Qin S, Cheng H, Feng J, Chen B, Cheng L, Lu Z, Ji J, Zhou Y.
    Am J Clin Oncol; 2010 Oct 01; 33(5):489-94. PubMed ID: 20351547
    [Abstract] [Full Text] [Related]

  • 13. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 01; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 14. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
    Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW.
    Lung Cancer; 2010 Aug 01; 69(2):155-64. PubMed ID: 19962780
    [Abstract] [Full Text] [Related]

  • 15. [Prognostic significance of ERCC1 mRNA expression in patients with non-small cell lung cancer receiving platinum-based chemotherapy].
    Qian XP, Liu BR, Shi MQ, Liu XZ, Hu WJ, Zou ZY, Wei J.
    Zhonghua Zhong Liu Za Zhi; 2009 Jan 01; 31(1):33-7. PubMed ID: 19538866
    [Abstract] [Full Text] [Related]

  • 16. Molecular Characteristics of ERCC1-Negative versus ERCC1-Positive Tumors in Resected NSCLC.
    Friboulet L, Barrios-Gonzales D, Commo F, Olaussen KA, Vagner S, Adam J, Goubar A, Dorvault N, Lazar V, Job B, Besse B, Validire P, Girard P, Lacroix L, Hasmats J, Dufour F, André F, Soria JC.
    Clin Cancer Res; 2011 Sep 01; 17(17):5562-72. PubMed ID: 21750204
    [Abstract] [Full Text] [Related]

  • 17. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S, Huo X, Lin Y, Ban H, Lin Y, Li W, Zhang B, Au WW, Xu X.
    Int J Hyg Environ Health; 2010 Mar 01; 213(2):140-5. PubMed ID: 20189873
    [Abstract] [Full Text] [Related]

  • 18. Excision repair cross complementing-group 1: gene expression and platinum resistance.
    Altaha R, Liang X, Yu JJ, Reed E.
    Int J Mol Med; 2004 Dec 01; 14(6):959-70. PubMed ID: 15547660
    [Abstract] [Full Text] [Related]

  • 19. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.
    Curr Opin Oncol; 2006 Mar 01; 18(2):135-43. PubMed ID: 16462182
    [Abstract] [Full Text] [Related]

  • 20. [Correlation between expression of excision repair cross-complementing 1 and cisplatin sensitivity in non-small cell lung cancer].
    Han XP, Zhang X.
    Zhonghua Yi Xue Za Zhi; 2010 Aug 10; 90(30):2115-8. PubMed ID: 21029626
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.